Researchers at each center collected data using an online questionnaire hosted at www.clinicalsurveys.net, EPICOVIDEHA is registered at http://www.clinicaltrials.gov, with the identifier NCT 04733729. Only de-identified data have been analyzed. Data collected included: age at transplantation (dichotomized as <50 years and ≥50 years), sex (male vs female), time from HSCT to the diagnosis of COVID-19, immunosuppression within 6 months of COVID-19 diagnosis, conditioning intensity (myeloablative vs reduced intensity), GVHD prophylaxis, time to engraftment, development of acute or chronic GVHD before COVID-19 diagnosis and immunodeficiency scoring index (ISI) at the time of COVID-19 infection. Clinically significant outcomes (hospital admission and intensive care unit [ICU] admission, vital status) were also evaluated. We did not collect information on treatment strategies of COVID-19.
Busca A., Salmanton-García J., Marchesi F., Farina F., Seval G.C., Van Doesum J., De Jonge N., Bahr N.C., Maertens J., Meletiadis J., Fracchiolla N.S., Weinbergerová B., Verga L., Ráčil Z., Jiménez M., Glenthøj A., Blennow O., Tanase A.D., Schönlein M., Prezioso L., Khanna N., Duarte R.F., Žák P., Nucci M., Machado M., Kulasekararaj A., Espigado I., De Kort E., Ribera-Santa Susana J.M., Marchetti M., Magliano G., Falces-Romero I., Ilhan O., Ammatuna E., Zompi S., Tsirigotis P., Antoniadou A., Zambrotta G.P., Nordlander A., Karlsson L.K., Hanakova M., Dragonetti G., Cabirta A., Berg Venemyr C., Gräfe S., Van Praet J., Tragiannidis A., Petzer V., López-García A., Itri F., Groh A., Gavriilaki E., Dargenio M., Rahimli L., Cornely O.A, & Pagano L. (2023). Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Frontiers in Immunology, 14, 1125030.
Corresponding Organization : University Hospital Cologne
Other organizations :
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Istituti di Ricovero e Cura a Carattere Scientifico, IRCCS Ospedale San Raffaele, Ankara University, University Medical Center Groningen, Amsterdam University Medical Centers, University of Kansas Medical Center, Universitair Ziekenhuis Leuven, KU Leuven, National and Kapodistrian University of Athens, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Masaryk University, University Hospital Brno, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, Institute of Haematology and Blood Transfusion, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Rigshospitalet, Copenhagen University Hospital, Karolinska University Hospital, University Medical Center Hamburg-Eppendorf, Universität Hamburg, University of Parma, University Hospital of Basel, Hospital Universitario Puerta de Hierro Majadahonda, University Hospital Hradec Králové, Universidade Federal do Rio de Janeiro, Hospital General Universitario Gregorio Marañón, King's College London, King's College Hospital, Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Radboud University Nijmegen, Radboud University Medical Center, Josep Carreras Leukaemia Research Institute, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Hospital Universitario La Paz, Agostino Gemelli University Polyclinic, AZ Sint-Jan, Aristotle University of Thessaloniki, Universität Innsbruck, Innsbruck Medical University, Hospital Universitario Fundación Jiménez Díaz, Ospedale San Luigi Gonzaga, University Hospital Frankfurt, Goethe University Frankfurt, G. Papanikolaou General Hospital, Ospedale Vito Fazzi, German Center for Infection Research, Università Cattolica del Sacro Cuore
Age at transplantation (dichotomized as <50 years and >=50 years)
Sex (male vs female)
Immunosuppression within 6 months of COVID-19 diagnosis
Conditioning intensity (myeloablative vs reduced intensity)
GVHD prophylaxis
Time to engraftment
Development of acute or chronic GVHD before COVID-19 diagnosis
Immunodeficiency scoring index (ISI) at the time of COVID-19 infection
dependent variables
Hospital admission
Intensive care unit (ICU) admission
Vital status
control variables
Time from HSCT to the diagnosis of COVID-19
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
